Chemistry:Deuterated testosterone

From HandWiki

Deuterated testosterone
Clinical data
Other namesAVA-291; AVA291; d-Testosterone; d3-Testosterone; d3-T; Deutestosterone; Testosterone-19-d3; 17β-Hydroxyandrost-4-en-3-one-19,19,19-D3
Routes of
administration
Oral, transdermal, parenteral[1]
Drug classAndrogen; Anabolic steroid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H28O2
Molar mass288.431 g·mol−1
3D model (JSmol)

Deuterated testosterone (developmental code name AVA-291), also known as d3-testosterone (d3-T), is an androgen or androgen receptor agonist which is under development for the treatment of breast cancer, female sexual dysfunction, hypogonadism, decreased libido, fatigue, and muscular atrophy.[1][2][3][4][5][6][7][8] It is taken orally, transdermally, or parenterally.[1]

The drug is an isotopologue of testosterone.[1][2][8] More specifically, the three hydrogen atoms on the C19 methyl group have been replaced with the deuterium isotopes.[1][8] Unlike testosterone, deuterated testosterone is highly resistant to metabolism into estradiol by aromatase, showing a half-life that is 4 to 7 times longer than that of testosterone in an aromatase-containing system in vitro (55.9–79.9 minutes vs. 7.7–18.5 minutes, respectively).[7][8] On the other hand, they were metabolized at similar rates in rat and human hepatocytes.[7][8][4] In addition, deuterated testosterone had similar potency and efficacy as testosterone as an androgen receptor agonist in vitro.[7][8] As such, deuterated testosterone is expected to retain activity as an androgen similarly to testosterone but to lack or have greatly reduced estrogenic activity.[4][7][8] Accordingly, deuterated testosterone showed 1,000-fold lower potential in stimulating breast cancer cell proliferation compared to testosterone.[4][9]

The chemical synthesis of deuterated testosterone has been described.[10][11][8]

Deuterated testosterone was first described in the scientific literature by 1978.[11] It is under development by Lennham Pharmaceuticals and Aviva Biopharm.[1][2][3][12] As of December 2025, the drug is in the preclinical research stage of development.[1][2][3] A phase 1 trial is being planned for early 2026.[2][4] Deuterated testosterone was patented in 2021.[6][8] It is expected to have improved tolerability and safety relative to testosterone in certain contexts, for instance avoiding gynecomastia (male breast development) or treating estrogen-sensitive breast cancer.[4][9][7][8]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Deuterated testosterone". 28 December 2025. https://adisinsight.springer.com/drugs/800065467. 
  2. 2.0 2.1 2.2 2.3 2.4 "AVA 291". 1 August 2025. https://adisinsight.springer.com/drugs/800083242. 
  3. 3.0 3.1 3.2 "Delving into the Latest Updates on d-Testosterone with Synapse". 16 May 2025. https://synapse.patsnap.com/drug/374be0a898364758b6005a1cf515d315. 
  4. 4.0 4.1 4.2 4.3 4.4 4.5 "FDA provides guidance on development pathway for testosterone therapy for women". 27 January 2026. https://www.urologytimes.com/view/fda-provides-guidance-on-development-pathway-for-testosterone-therapy-for-women. 
  5. "Weighty times ahead for the lab?". TIAFT Bulletin 52 (4). 2022. https://www.bioscientia.de/media/qr0onwah/deuterated-drugs-weighty-times_tiaft-bulletin_2022.pdf. Retrieved 27 January 2026. 
  6. 6.0 6.1 "Lennham discloses deuterated testosterone compound". 11 November 2021. https://www.bioworld.com/articles/686257-lennham-discloses-deuterated-testosterone-compound?v=preview. 
  7. 7.0 7.1 7.2 7.3 7.4 7.5 "MON-261 Characterization of d3-Testosterone, A Novel, Non-Aromatizing Androgen". Journal of the Endocrine Society 9 (Supplement_1). 22 October 2025. doi:10.1210/jendso/bvaf149.1839. ISSN 2472-1972. 
  8. 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 "Deuterated forms of testosterone and methods of use". 23 March 2021. https://patents.google.com/patent/US11202785B1. 
  9. 9.0 9.1 "Aviva to advance, announce new data for AVA-291 women's testosterone therapy". 27 January 2026. https://www.contemporaryobgyn.net/view/aviva-to-advance-announce-new-data-for-ava-291-women-s-testosterone-therapy. 
  10. "A unified total synthesis route to 18-trideuterated and/or 19-trideuterated testosterone, androstenedione and progesterone". Steroids 205. May 2024. doi:10.1016/j.steroids.2024.109391. PMID 38437943. 
  11. 11.0 11.1 "Synthesis of trideuterated testosterone labeled selectively at the C-19 angular methyl group". Journal of Labelled Compounds and Radiopharmaceuticals 14 (5): 783–791. 1978. doi:10.1002/jlcr.2580140517. ISSN 0362-4803. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jlcr.2580140517. Retrieved 27 January 2026. 
  12. "Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025". 14 July 2025. https://www.businesswire.com/news/home/20250714405897/en/Aviva-Biopharm-Inc.-Unveils-Groundbreaking-Pre-Clinical-Data-on-d3-T-a-First-in-Class-Testosterone-Therapy-for-Women-at-ENDO-2025. 

{{Navbox

| name = Androgens and antiandrogens
| title = Androgens and antiandrogens
| state = collapsed
| listclass = hlist
| groupstyle = text-align:center;
| group1 = Androgens
(incl. AAS)

| list1 =

  | group3 = Antigonadotropins
  | list3 =
  | group4 = Others
  | list4 =
}}
| liststyle = background:#DDDDFF;
| list3 =
See also
Androgen receptor modulators
Estrogens and antiestrogens
Progestogens and antiprogestogens
List of androgens/anabolic steroids

}}